XaTek Inc. raises $9.1 million to advance technology that measures blood’s clotting ability

XaTek Inc., a Cleveland-based biomedical company, recently raised $9.1 million in Series A capital to advance and test the device it’s developing called ClotChip — a portable sensing system that can quickly assess the clotting ability of a person’s blood.

The funding will support the completion of XaTek’s first commercial product, including clinical trials and filing for U.S. Food and Drug Administration clearance for uses in hemophilia and anticoagulation therapy by mid-2021, according to a news release.

Click here to read the complete article and read more in The Plain Dealer.
Story excerpt provided by Crain’s Cleveland Business.
Written by Lydia Coutre.
Originally published July 11, 2018.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: